Pancreatic cancer 2

Common Name(s)

Pancreatic cancer 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 2" returned 166 free, full-text research articles on human participants. First 3 results:

Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.
 

Author(s): Hong-Quan Duong, Yong Weon Yi, Hyo Jin Kang, Insoo Bae, Young-Joo Jang, Sahng-June Kwak, Yeon-Sun Seong

Journal: Int. J. Oncol.. 2014 Jun;44(6):2132-8.

 

Gemcitabine-based chemotherapy is the standard for treatment of pancreatic cancer; however, intrinsic and acquired resistance to gemcitabine commonly occurs. Aldehyde dehydrogenase 1A1 (ALDH1A1), one of the characteristic features of tumor-initiating and/or cancer stem cell (CSC) ...

Last Updated: 15 Apr 2014

Go To URL
Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2.
 

Author(s): Dorrah Deeb, Xiaohua Gao, Yong Bo Liu, Kirit Pindolia, Subhash C Gautam

Journal: Int. J. Oncol.. 2014 May;44(5):1707-15.

 

Lack of effective therapeutics for pancreatic cancer at the present time underscores the dire need for safe and effective agents for the treatment of this malignancy. In the present study, we have evaluated the anticancer activity and the mechanism of action of pristimerin (PM), a ...

Last Updated: 19 Mar 2014

Go To URL
Chlorotoxin-Fc fusion inhibits release of MMP-2 from pancreatic cancer cells.
 

Author(s): Samah El-Ghlban, Tomonari Kasai, Tsukasa Shigehiro, Hong Xia Yin, Sreeja Sekhar, Mikiko Ida, Anna Sanchez, Akifumi Mizutani, Takayuki Kudoh, Hiroshi Murakami, Masaharu Seno

Journal: Biomed Res Int. 2014 ;2014():152659.

 

Chlorotoxin (CTX) is a 36-amino acid peptide derived from Leiurus quinquestriatus (scorpion) venom, which inhibits low-conductance chloride channels in colonic epithelial cells. It has been reported that CTX also binds to matrix metalloproteinase-2 (MMP-2), membrane type-1 MMP, and ...

Last Updated: 10 Feb 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 2" returned 3 free, full-text review articles on human participants. First 3 results:

Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
 

Author(s): John R Hornick, Dirk Spitzer, Peter Goedegebuure, Robert H Mach, William G Hawkins

Journal: Surgery. 2012 Sep;152(3 Suppl 1):S152-6.

 

One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ...

Last Updated: 21 Aug 2012

Go To URL
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
 

Author(s): Muhammad Wasif Saif

Journal:

 

Despite attempted curative resection of localized pancreatic adenocarcinoma, most patients succumb a recurrence and die of their disease. The Gastrointestinal Tumor Study Group, European Organization for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer ...

Last Updated: 7 Jul 2009

Go To URL
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
 

Author(s): M Mimeault, S K Batra

Journal: Gut. 2008 Oct;57(10):1456-68.

 

Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem ...

Last Updated: 15 Sep 2008

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Pancreatic Cancer Early Detection Program
 

Status: Recruiting

Condition Summary: Pancreatic Cancer; Pancreas Cancer; Pancreatic Adenocarcinoma; Familial Pancreatic Cancer; BRCA 1/2; HNPCC; Lynch Syndrome; Hereditary Pancreatitis; FAMMM; Familial Atypical Multiple Mole Melanoma; Peutz Jeghers Syndrome

 

Last Updated: 30 Jul 2014

Go to URL
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
 

Status: Recruiting

Condition Summary: BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer

 

Last Updated: 15 Dec 2014

Go to URL
Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
 

Status: Recruiting

Condition Summary: Bile Duct Cancer; Pancreatic Cancer

 

Last Updated: 4 Dec 2013

Go to URL